INSP — Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. (INSP) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $269 million, up 12% year-over-year.
• Full Year Revenue: $912 million, up 14%.
• Operating Margin: Improved due to sales leverage and a higher mix of Inspire 5 systems.
• Net Income per Diluted Share: Q4 increased to $4.66 (+$3.51 YoY); Full year increased to $4.89 (+$3.09 YoY).
• Adjusted Net Income per Diluted Share: Q4 at $1.65 (+$0.51 YoY); Full year at $2.42 (+$0.80 YoY).
• Operating Cash Flow: Q4 at $52 million; Full year at $117 million.
• Share Repurchases: $50 million in Q4, totaling $175 million for the year.
• Cash and Investments: Ended Q4 with $405 million.

2. Strategic Updates and Business Highlights

• Reimbursement Challenges: Transitioning to CPT code 64582 with a -52 modifier for the Inspire 5 procedure, which may reduce professional fees by 10% to 50%.
• Inspire 5 Launch: Strong performance with over 90% of centers now implanting the Inspire 5 system. Physician training and contracting are largely complete.
• Patient Demand: Increased social media activity and patient marketing efforts contributed to a strong finish in 2025.
• R&D Initiatives: New features for Inspire 6 are in development, including sleep detection and auto-activation.
• WISER Program: A government initiative requiring prior authorization for Medicare cases, affecting procedures in six pilot states.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Revised to $950 million to $1,000 million, reflecting a growth rate of 4% to 10%. This range accounts for potential impacts from coding uncertainty and the new reimbursement landscape.
• First Quarter 2026 Expectations: Revenue expected to be flat compared to the prior year, with a net loss anticipated due to higher operating expenses.
• Adjusted Operating Margin: Projected between 6% to 8% for 2026.

4. Bad News, Challenges, or Points of Concern

• Reimbursement Uncertainty: The transition to the -52 modifier may significantly impact physician willingness to perform procedures, potentially limiting case volumes.
• WISER Program Disruptions: Initial challenges with prior authorizations have caused delays in Medicare patient procedures.
• Competitive Pressures: The company is aware of competition and is actively monitoring market dynamics, but remains confident in its product's effectiveness.
• Inventory Management: While there is sufficient inventory of Inspire 4 systems, the company is focused on transitioning to Inspire 5, which may limit flexibility.

5. Notable Q&A Insights

• Clarity on Coding: Management emphasized the importance of clarity in reimbursement codes and is actively working with MACs and commercial payers to minimize reductions in professional fees.
• Physician Feedback: Majority of physicians are in private practice, and those in academic centers are less impacted by fee reductions. The company is working to ensure that private practice physicians remain willing to perform procedures.
• Long-term Strategy: The pursuit of a new CPT code is seen as essential for long-term reimbursement stability, with the expectation that the new code could be in place by 2028.
• Market Dynamics: Management expressed confidence in Inspire 5's clinical data and its ability to drive patient demand, despite current reimbursement challenges.

This summary captures the essential financial performance, strategic initiatives, and challenges facing Inspire Medical Systems as they navigate a complex reimbursement landscape while continuing to innovate and expand their market presence.